Genmab As Stock Current Valuation
| GMAB Stock | USD 19.76 0.08 0.40% |
Valuation analysis of Genmab AS helps investors to measure Genmab AS's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value Over EBITDA is expected to grow to 13.24. The current year's Enterprise Value Multiple is expected to grow to 13.24. Fundamental drivers impacting Genmab AS's valuation include:
Overvalued
Today
Please note that Genmab AS's price fluctuation is not too volatile at this time. Calculation of the real value of Genmab AS is based on 3 months time horizon. Increasing Genmab AS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Genmab AS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genmab Stock. However, Genmab AS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.76 | Real 17.33 | Target 36.56 | Hype 19.84 | Naive 17.95 |
The real value of Genmab Stock, also known as its intrinsic value, is the underlying worth of Genmab AS Company, which is reflected in its stock price. It is based on Genmab AS's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Genmab AS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Genmab AS helps investors to forecast how Genmab stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genmab AS more accurately as focusing exclusively on Genmab AS's fundamentals will not take into account other important factors: Genmab AS Company Current Valuation Analysis
Genmab AS's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Genmab AS Current Valuation | 9.89 B |
Most of Genmab AS's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Genmab Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Genmab AS is extremely important. It helps to project a fair market value of Genmab Stock properly, considering its historical fundamentals such as Current Valuation. Since Genmab AS's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Genmab AS's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Genmab AS's interrelated accounts and indicators.
Click cells to compare fundamentals
Genmab Current Valuation Historical Pattern
Today, most investors in Genmab AS Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Genmab AS's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Genmab AS current valuation as a starting point in their analysis.
Genmab AS Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Genmab AS has a Current Valuation of 9.89 B. This is 31.11% lower than that of the Biotechnology sector and 112.99% higher than that of the Health Care industry. The current valuation for all United States stocks is 40.48% higher than that of the company.
Genmab Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genmab AS's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics of similar companies.Genmab AS is currently under evaluation in current valuation category among its peers.
Genmab AS ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Genmab AS's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Genmab AS's managers, analysts, and investors.Environmental | Governance | Social |
Genmab Fundamentals
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.36 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 9.89 B | ||||
| Shares Outstanding | 635.5 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 9.30 % | ||||
| Number Of Shares Shorted | 1.65 M | ||||
| Price To Earning | 66.53 X | ||||
| Price To Book | 2.40 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 21.53 B | ||||
| Gross Profit | 20.54 B | ||||
| EBITDA | 7.39 B | ||||
| Net Income | 7.84 B | ||||
| Cash And Equivalents | 21.61 B | ||||
| Cash Per Share | 33.05 X | ||||
| Total Debt | 1.03 B | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 13.11 X | ||||
| Book Value Per Share | 577.54 X | ||||
| Cash Flow From Operations | 7.77 B | ||||
| Short Ratio | 1.34 X | ||||
| Earnings Per Share | 1.78 X | ||||
| Price To Earnings To Growth | 1.10 X | ||||
| Target Price | 31.0 | ||||
| Number Of Employees | 2.68 K | ||||
| Beta | 0.9 | ||||
| Market Capitalization | 12.75 B | ||||
| Total Asset | 45.81 B | ||||
| Retained Earnings | 23.55 B | ||||
| Working Capital | 22.55 B | ||||
| Current Asset | 12.65 B | ||||
| Current Liabilities | 823.51 M | ||||
| Net Asset | 45.81 B |
About Genmab AS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Genmab AS Piotroski F Score and Genmab AS Altman Z Score analysis. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.634 | Earnings Share 1.78 | Revenue Per Share | Quarterly Revenue Growth 0.353 | Return On Assets |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.